Who are Lovenox (Preservative Free)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Heparin Sodium In Plastic Container, Lovenox, Arixtra, Enoxaparin, half amount low molecular weight heparin, Fragmin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/enoxaparin-sodium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Lovenox (Preservative Free) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lovenox (Preservative Free) (ENOXAPARIN SODIUM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low Molecular Weight Heparin. Area: Cardiovascular.

marketed Low Molecular Weight Heparin Antithrombin-III Cardiovascular Oligosaccharide Live · refreshed every 30 min

Target snapshot

Lovenox (Preservative Free) (ENOXAPARIN SODIUM) — Sanofi. Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lovenox (Preservative Free) TARGET	ENOXAPARIN SODIUM	Sanofi	marketed	Low Molecular Weight Heparin	Antithrombin-III	1993-01-01
Heparin Sodium In Plastic Container	HEPARIN	Merck & Co.	marketed	Anti-coagulant	Antithrombin-III	1939-01-01
Lovenox	Lovenox	University of Monastir	marketed		Antithrombin-III
Arixtra	Arixtra	LifeBridge Health	marketed		Antithrombin-III, Coagulation factor X
Enoxaparin	Enoxaparin	Dana-Farber Cancer Institute	marketed		Antithrombin-III
half amount low molecular weight heparin	half amount low molecular weight heparin	Beijing Anzhen Hospital	marketed	Anticoagulant (low molecular weight heparin)	Antithrombin III (indirect target); Factor Xa and Factor IIa (downstream targets)
Fragmin	Dalteparin Sodium	Pfizer Inc.	marketed	Low molecular weight heparin (LMWH)	Factor Xa and thrombin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low Molecular Weight Heparin class)

Pfizer · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lovenox (Preservative Free) — Competitive Intelligence Brief. https://druglandscape.com/ci/enoxaparin-sodium. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing